東瑞製藥(02348.HK)擬1.04億元出售蘇州東瑞醫藥科技65%權益
格隆匯7月30日丨東瑞製藥(02348.HK)公吿,於2021年7月30日,東瑞國際股份有限公司(集團全資附屬公司)(作為賣方)、蘇州融新建設發展有限公司(獨立第三方(一間由中國蘇州吳中經濟開發區地方政府最終擁有的房地產開發商))(作為買方),以及蘇州東瑞醫藥科技有限公司(蘇州東瑞醫藥科技)(集團全資附屬公司)就出售集團於蘇州東瑞醫藥科技的65%權益訂立買賣協議,總代價為人民幣1.04億元。
蘇州東瑞醫藥科技的註冊資本為美金600萬元及主要為集團位於中國蘇州的生產工廠提供溶媒回收服務。當地政府已要求集團的蘇州附屬公司將其生產工廠遷至蘇州吳中經濟開發區另一地段。
預期隨着技術升級,蘇州東瑞醫藥科技的生產功能將整合到新建成的生產基地。於該出售完成後,蘇州東瑞醫藥科技將不再為集團附屬公司,估計集團將確認該出售收益約人民幣6461萬元(約相當於港幣7775萬元)。集團將對其在蘇州東瑞醫藥科技剩餘的35%權益採用權益法核算。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.